New 'Living Drug' trial offers hope for Tough-to-Treat liver cancer
NCT ID NCT06590246
Summary
This study is testing a new type of personalized cell therapy called C-CAR031 for adults with advanced liver cancer that has come back or stopped responding to standard treatments. Doctors will take a patient's own immune cells, modify them in a lab to better target the cancer, and then infuse them back into the body. The main goals are to see if the treatment is safe and if it can shrink or control the tumors in patients who have few other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHanzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
ZhongShan Hospital Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.